Camporesi Anna, Morello Rosa, Ferro Valentina, Pierantoni Luca, Rocca Alessandro, Lanari Marcello, Trobia Gian Luca, Sciacca Tiziana, Bellinvia Agata Giuseppina, De Ferrari Alessandra, Valentini Piero, Roland Damian, Buonsenso Danilo
Anesthesia and Intensive Care Unit, "Vittore Buzzi" Children's Hospital, 20154 Milan, Italy.
Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Children (Basel). 2022 Apr 1;9(4):491. doi: 10.3390/children9040491.
The aim of this study was to understand the epidemiology, disease severity, and microbiology of bronchiolitis in Italy during the 2021-2022 cold season, outside of lockdowns. Before COVID-19, the usual bronchiolitis season in Italy would begin in November and end in April, peaking in February. We performed a prospective observational study in four referral pediatric centers located in different geographical areas in Italy (two in the north, one in the center and one in the south). From 1 July 2021 to 31 January 2022, we collected all new clinical diagnoses of bronchiolitis in children younger than two years of age recording demographic, clinical and microbiological data. A total of 657 children with a clinical diagnosis of bronchiolitis were enrolled; 56% children were admitted and 5.9% required PICU admission. The first cases were detected during the summer, peaking in November 2021 and declining into December 2021 with only a few cases detected in January 2022. RSV was the commonest etiological agent, while SARS-CoV-2 was rarely detected and only since the end of December 2021. Disease severity was similar in children with RSV vs. non-RSV bronchiolitis, and in those with a single infectious agent detected compared with children with co-infections. The 2021-2022 bronchiolitis season in Italy started and peaked earlier than the usual pre-pandemic seasons, but had a shorter duration. Importantly, the current bronchiolitis season was not more severe when data were compared with Italian published data, and SARS-CoV-2 was rarely a cause of bronchiolitis in children younger than 24 months of age.
本研究旨在了解2021-2022年寒冷季节意大利在解除封锁状态下细支气管炎的流行病学、疾病严重程度和微生物学情况。在新冠疫情之前,意大利通常的细支气管炎季节从11月开始,4月结束,2月达到高峰。我们在意大利不同地理区域的四个儿科转诊中心进行了一项前瞻性观察研究(两个在北部,一个在中部,一个在南部)。从2021年7月1日至2022年1月31日,我们收集了所有2岁以下儿童新的细支气管炎临床诊断病例,并记录了人口统计学、临床和微生物学数据。共纳入657例临床诊断为细支气管炎的儿童;56%的儿童入院治疗,5.9%的儿童需要入住儿科重症监护病房(PICU)。首例病例在夏季被检测到,2021年11月达到高峰,随后在2021年12月下降,2022年1月仅检测到少数病例。呼吸道合胞病毒(RSV)是最常见的病原体,而严重急性呼吸综合征冠状病毒2(SARS-CoV-2)很少被检测到,且仅在2021年12月底之后才出现。RSV感染与非RSV感染的细支气管炎患儿的疾病严重程度相似,单一病原体感染患儿与合并感染患儿的疾病严重程度也相似。意大利2021-2022年的细支气管炎季节开始时间和高峰时间均早于疫情前的通常季节,但持续时间较短。重要的是,与意大利已发表的数据相比,当前细支气管炎季节的严重程度并未增加,且SARS-CoV-2很少是24个月以下儿童细支气管炎的病因。